FAP, June 6 (FAP)-- Today, a reporter from the Financial Associated Press learned from Notai Biology as an investor. At present, the company has Smeagruptide and Lilaruptide API products, both of which contribute a small proportion of total revenue, while Simigrup API is limited by the patent protection of Simigrup injection. At present, it mainly has supply cooperation for research purposes with three or four domestic head imitation pharmaceutical companies, and the company has successfully raised funds and drawn up a plan for the development of the production line of Simigrup APIs. Small financial note: recently, Novox Megler peptide injection application was officially accepted by the CDE, the industry rumors of new weight loss indications. (financial Associated Press reporter Lu Afeng)